$40 billion: Merck rumored to buy Seagen
- Moderna Latest Study: mRNA Therapy for Treating T Cell-Mediated Autoimmune Diseases
- The Biosecure Act May Hurt Pharmaceutical Supply Chains
- Mosquito Elimination on Global Health: Unraveling the Claim of 700K Annual Deaths
- Intensive Blood Pressure Management to Below 140 mmHg Reduces Stroke Risk, Regardless of Medication Dosage
- GLP-1 Drugs: How Significant is Their Impact on Brain Health?
- Why Eel Sashimi Is Unsafe: Understanding the Risks of Consuming Raw Eel
$40 billion: Merck rumored to buy Seagen
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
$40 billion: Merck rumored to buy Seagen
Merck is in advanced talks to buy Seagen and plans to reach an agreement in the coming weeks to acquire the cancer biotech company in a deal that could total about $40 billion or more, according to a report in the Wall Street Journal, citing people familiar with the matter.
Merck is in advanced talks to buy Seagen and plans to reach an agreement in the coming weeks to acquire the cancer biotech company in a deal that could total about $40 billion or more, according to a report in the Wall Street Journal, citing people familiar with the matter.
The two companies are negotiating a purchase price above $200 a share and are seeking to reach an agreement on or before Merck & Co. reports its second-quarter fiscal 2022 report on July 28, people familiar with the matter said.
As of the close of U.S. stocks on July 7, 2022, Merck’s shares fell slightly by 0.13% to $93.01 per share, and Seagen’s shares rose 1.61% to $177.95 per share.
But it is worth noting that even if the two sides reach an agreement, the final settlement of the transaction still needs to pass the antitrust review of the United States.
As early as June 18, 2022, according to the Wall Street Journal, Merck is considering acquiring Seagen, the leading ADC company.
Merck and Seagen have previously formed a partnership. In September 2020, Merck introduced the LIV-1-targeting antibody-drug conjugate (ADC) ladiratuzumab vedotin, with a total transaction value of $4.5 billion, including a $600 million down payment, a $1 billion equity investment, and a maximum of $2.6 billion in mileage.
At the same time, Merck acquired the rights to commercialize the tyrosine kinase inhibitor tucatinib in Asia, the Middle East and Latin America, and other regions (outside the U.S., Canada and Europe) for $190 million.
Seagen is a leader in the ADC field. Currently, 4 new ADC drugs (3 independent research and 1 cooperative development) have been approved for marketing, and there are many new ADC drugs under development. In 2021, the sales revenue of the listed products for Seagen will be 1.38 billion US dollars.
$40 billion: Merck rumored to buy Seagen
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
